Yingpai Pharmaceutical Baojun: From BD Leader to CEO

Text . . Dr. Shyi Baojun is currently the CEO of Yingpai Pharmaceuticals.
has extensive experience in drug development, technology transfer, licensing and business development, venture capital, entrepreneurship and corporate finance.
I was a Wollongong loose man, because a new BD seed sprouted and became CEO.
- Bao Jun five years ago, I received a material, let me according to the information for Dr. Bao Jun to write a character manuscript.
then, just between the lines of the word, a in the medicine, full of witty BD master image has leapt on paper.
five years, China's innovative pharmaceutical environment has undergone major and profound changes, and as the earliest participants and witnesses of these changes, Dr. Bao Jun's identity has undergone important changes in the past five years.
He has admitted that the excellent BD is the best CEO successor, but he is more inclined to do a good job of BD as a strategist, hoping to be like Zhu Geliang for the sage Liu Preparing to do a good job of staff, rather than directly ordered, with soldiers to fight.
, however, the story always develops with some surprise and some fate.
In October 2018, Yingpai Pharmaceuticals officially announced the appointment of Dr. Bao Jun as CEO, in order to promote the company's domestic and foreign business development, the news came out, causing strong concern in the industry, many people are as curious as I am: what makes this habitual BD master, willing to take on the burden, become a company's helm? And after hanging up the CEO, what has changed in Bao Jun's role? In 2020, on the eve of the new research and development day of The British Pharmaceuticals, Dr. Bao Jun officially gave an exclusive interview to Sina Pharmaceuticals, telling us many of the stories behind it.
a long-term heart knot A brand new journey This interview is located in a conference room next to the Oriental Pearl of Shanghai.
through the window of the interview room, Lujiazui's financial district is bright and charming at night, and every shining light seems to show the world Shanghai's open, inclusive, dynamic temperament.
return to a more fresh and dynamic Shanghai, which Mr. Bao had long wanted, before he served as senior vice president and chief commercial officer of Aoki Pharmaceuticals in Beijing.
Baojun admitted that the deeper reason to join the British pharmaceutical industry is from his long-term heart knot.
He has said that many of the projects he has led in China have been stranded for various reasons, and that it is a great pity that he has not completed a particularly large BD deal in China and has not succeeded in working with innovative pharmaceutical companies founded by returning scientists in China.
this, Dr. Bao Jun also recalled a little-known story for us: as early as 2006, Bao Jun, who also works for a U.S. pharmaceutical company, has begun to pay attention to and contact with domestic projects.
it wasn't long before he discovered a new drug, 971, from Qingdao Ocean University, which was developed by a team of Chinese experts and is expected to be the first original innovation in China to treat Alzheimer's disease.
years of BD experience, Bao Jun is keenly aware that this is a very promising and innovative drug, whether from research and development direction, mechanism logic or clinical data.
he was overjoyed and even decided to return home to start a business! It is worth mentioning that in China at that time, it was a bold initiative to draw a project out of the Institute and set up a separate company to research and development.
And we can also see from Dr. Post-Bread Jun's work resume that for a man who doesn't like to fight with soldiers, the experience of discovering projects and wanting to start his own business is really rare, and perhaps that's what confirms his bullish view of the new drug.
, however, just as Bao Jun was preparing for a big fight, in 2008, when the global financial turmoil hit, the 971 project encountered financing difficulties and had to be transferred to Green Valley Pharmaceuticals.
after more than 10 years, in 2019, Green Valley Pharmaceutical GV-971 was conditionly approved by the State Drug Administration for listing, although GV-971 was approved with a variety of disputes, but Judging from the results of the trial alone, because the clinical phase 3 positive results, Bao Jun is still optimistic about the ongoing global multi-center phase 3 clinical results, believe that the future of the new drug is still expected to achieve industrialization, he is also proud to excavate this new drug at a very early stage.
even though Bao Jun cut the 971 project because of the financial turmoil, he had already felt the new vitality of China's innovative medicine.
He became more actively involved in the business and has repeatedly worked as a commercial planner for start-ups such as Hua-Li Pharmaceuticals (focusing on diabetes), Hai and Bio (focusing on innovative drugs on oncology), and although he didn't start a business together in the end, Bao jun is still very happy to see the two companies now making progress on their respective tracks.
been engaged in BD for many years, whether to find a good project and see it blossom, has always been the most important thing for Bao Jun.
is also based on such ambitions, Bao Jun and Yingpai pharmaceutical industry's fate began.
Baojun's contract with the current core management team of Yingpai Pharmaceuticals is about to expire.
we do in the future? Bao Jun originally planned not only for a company to do BD, but to join a platform to do BD for a number of companies, so that there is more and more free play space to mobilize their own resources.
, however, a new BD seed, Synthetic Death, changed his plans.
that time, Lilly Asia Fund found Bao Jun, hoping that he would join the British Pharmaceuticals and serve as CEO, had been determined not to be CEO Bao Jun, because the British Pharmaceuticals' core asset, PARP inhibitors began to move.
PARP inhibitors are the first drugs to be clinically successful using the concept of "synthetic death".
statistics, in the first three quarters of 2020 BD transaction TOP10, "synthetic death" category of targets occupy two seats, is currently the world's many pharmaceutical giants, but in China, "synthetic death" is still a more cutting-edge research direction in the field of anti-tumor drugs.
"working on BD for so many years, can you practice your own vision?" "From the outside, the British pharmaceutical industry is a 'PARP inhibitor', can the BD transaction, starting with PARP inhibitors, to create a world-leading 'synthetic death' company?" "The two founders of Yingpai Pharmaceuticals are focused on research and development, can you work with them in business development, corporate management, and try to be CEO?" ...... After some consideration, Bao Jun carefully put the pieces in the British pharmaceutical industry, and personally hang up the handsome expedition.
From Wollongong to the shoulder-to-shoulder BD period, a successful BD deal was like a wonderful master trick, a behind-the-scenes battle of vision, professionalism and strategy;
first is strategic decision-making.
In Bao Jun's view:
BD is a strategist, the CEO is a strategist, but the CEO's strategy is not a single decision, but a continuous decision-making process and the courage and perseverance of all in (full investment of resources).
" before he was like a big wave of gold treasure hunt, a year to see at least 200 projects, half an hour to kill one, find a good project can be successful, happy and decisive.
but now he's more of a leader of a mountaineering team. What rhythm? With whom? ...... He needs to face these problems constantly, some choices even need to be difficult to choose, and once decided, it must be resolutely implemented! Sprint faster! In order to reach the top as soon as possible, to achieve success.
was followed by platoon formations.
Liu Preparing once commented on Zhu Geliang: "Lonely has Kongming, Utah fish have water also."
" good talent is Bao Jun's work over the years hope.
now identity exchange, "knowing people to make good use of" has become a compulsory course for him.
"Because everyone has expertise, it's very difficult to get everyone to use it well, to satisfy his or her role, and to see the room for growth, " Bao said with emotion.
took over as CEO of Yingpai Pharmaceuticals for some time, Bao Jun made an important personnel change at the company.
he made adjustments to the position of a senior senior in the company.
the original employee was a scientist, but because the company was just starting out, the employee in addition to doing scientific research, but also to devote energy to financing and operations, often in a number of positions.
"in order to let the best people in their areas of expertise to play their strengths.
" Bao Jun said that even if the original intention is good, but because of business changes, easy to make people think other, so he took extra care to deal with this matter.
, he talked to the employee several times, dispelled the other person's concerns, and finally found a satisfactory role for the other person.
Baojun firmly believes that talent is the cornerstone of development, in addition to paying special attention to cherish talent, he also likes to tap new people.
2020 Yingpai Pharmaceutical Research and Development Day Bao Jun speech before Bao Jun active on the podium, always thick and thin hair, side-by-side recruitment of the preaching industry to demystify, in the early days of China's innovative drugs, training affected a batch of BD talent in China.
he is now active on the podium, beginning to run more for the British pharmaceutical industry, spare no effort to show the world the "synthetic death" of the field of major discoveries, hoping to benefit patients as soon as possible.
Although he has devoted himself to the cause of "synthetic death", but Bao Jun bone still feel that he is still the one who enjoys food, enjoy life, smart, he laughs: "I was a Wollongong loose man, now provoke As CEO, I'm happy to have developed The British Pharmaceuticals from a small company with a single product to a leader in the field of 'synthetic death', because it at least proves that my vision , 'synthetic death', is in the right direction.
as far as other commercial planning is about, I see it lightly.
"If there are some lucky chances of Bao Jun becoming ceo of Yingpai Pharmaceuticals, then the sples in his bones is the result of a long-term personality.
looking back when the tide is sailing today's China, the sky is high and the sea wide.
standing at the end of 2020 this special time node or look back, or look out, the history of the long river magnificent, Bohai Santian, the brush of time detailed outline of China's innovative pharmaceutical industry every step of the growth footprint.
as the earliest group of participants and witnesses, Bao Jun's career footprint and these change trajectories are mutually referenced and confirmed to each other.
Before studying in the United States, Bao Jun time goes back more than 30 years, because of his love of biology, Bao Jun enrolled in China's first department of microbiology - Shandong University microbiology, and then experienced the Shanghai Chinese Academy of Sciences 3 years master's degree - go abroad to further neurobiology - Johns Hopkins Medical College postdoctoral, over the years in the long road of scientific research constantly seeking.
in such an era, college students have been "the son of heaven and son", learning through the West is rare, is a well-deserved elite of the times.
calm, elegant and wise, probably the struggle of the era to his brand under the character of the background color.
, however, because from a young love to read "hybrid books", involved in a wide range of, Bao Jun's personality in a more one-man sky, the heart of the world is more all-encrusted.
S. Bao Jun, who was studying in Chicago, was originally engaged in scientific research in the laboratory, because he wanted to get in touch with the larger world, determined to get out of the lab where he had been struggling for years, to study for an MBA at the University of Chicago, and grow into an excellent BD step by step.
after absorbing foreign advanced technology concepts, more care, concern about the current situation of domestic development, and then firmly back home, step by step to today.
a blink of an eye, Bao Jun, who had been studying for a master's degree in Shanghai, returned to Shanghai to fight again.
more than thirty years of vicissitudes of change, more than thirty years of waves.
the Huangpu River, there are still ups and downs, but today's China's innovative pharmaceutical industry has shown its courage and strength to the world with unprecedented creativity.
generations of medics like Bao Jun are driving this great cause into a broader future under great uncertainty.
the future of the growing British pharmaceutical industry will certainly continue to fight the market competition in such a wave of times, and the elegant Dr. Bao Jun will bring us what kind of surprise? Maybe the answer is in the next five years, the next decade.
"The Story of the Romans" reading notes The ancient Romans' obsession with the system is impressive, whether it is the election of public office, or the military camp, they all have their own laws, but also strictly enforced.
The Romans made an in-depth study of the Greek system of government, decided not to adopt the Greek democratic system of government, but to establish a republic with rights constraints, but also to ensure the efficient operation of the government, two thousand years ago, really worthy of the great creation of mankind.
for hundreds of years, the heroes of the nation, and each time the whole country united around the leaders.
- Bao Jun 2020.11.21 attached to the book "The Story of the Romans" The ancient Romans' obsession with the system is impressive, whether it is the election of public office, or marching camp, they all have their own rules, but also strictly enforced.
The Romans made an in-depth study of the Greek system of government, decided not to adopt the Greek democratic system of government, but to establish a republic with rights constraints, but also to ensure the efficient operation of the government, two thousand years ago, really worthy of the great creation of mankind.
for hundreds of years, the heroes of the nation, and each time the whole country united around the leaders.
- Bao Jun 2020.11.21 For more on British Pharmaceuticals and Synthetic Death, click: British Pharmaceuticals: Small Molecules Make a Big Impact to Build the World's Leading "Synthetic Death" Portfolio